Skip to main content
HBIO
NASDAQ Life Sciences

哈佛生物科学报告56.7M FY25 净亏损由商誉损失驱动；收入下降

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$0.499
Mkt Cap
$22.677M
52W Low
$0.281
52W High
$0.946
Market data snapshot near publication time

summarizeSummary

哈佛生物科学宣布其第四季度和2025年全年财务结果，报告全年净亏损为56.7百万美元，主要由2025年第一季度4,800万美元的商誉损失驱动。全年收入从2024年的9,410万美元下降到8,660万美元，第四季度收入也从去年的2,460万美元下降到2,370万美元。虽然调整后的EBITDA在两个期间都有所改善，但巨大的净亏损和收入收缩表明运营存在挑战。该公司提供了2026年第一季度的收入预测，预计收入在2,000万美元至2,200万美元之间，预计2026年全年的收入将增长2-4%，这取决于向转化科学和新产品创新进行战略转变。交易者将关注公司执行这一战略转变的能力以及扭转收入下降和提高盈利能力的能力。

在该公告发布时，HBIO的交易价格为$0.50，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2267.7万。 52周交易区间为$0.28至$0.95。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed HBIO - Latest Insights

HBIO
Apr 21, 2026, 4:58 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Stockholders to Vote on Authorizing 520,000 New Shares for Employee Incentive Plans
Sentiment: Neutral
View Wiseek Article
HBIO
Apr 21, 2026, 4:56 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Shareholders to Vote on Significant Equity Plan Share Increases
Sentiment: Neutral
View Wiseek Article
HBIO
Apr 01, 2026, 9:44 AM EDT
Filing Type: 4
Importance Score:
7
CFO Mark Frost Buys $25,000 in Harvard Bioscience Stock Amidst Recent Insider Accumulation
Sentiment: Positive
View Wiseek Article
HBIO
Mar 23, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
BroadOak Funds and Director Snider Disclose 15.97% Stake via Convertible Debt and Warrants, Securing Company Financing
Sentiment: Neutral
View Wiseek Article
HBIO
Mar 18, 2026, 2:13 PM EDT
Filing Type: 4
Importance Score:
8
Director Stephen Denelsky Buys $48.7K in Stock, Joining Recent Insider Accumulation
Sentiment: Positive
View Wiseek Article
HBIO
Mar 18, 2026, 7:31 AM EDT
Filing Type: 4
Importance Score:
7
Director William Snider Buys Over $103K in Harvard Bioscience Stock Post-Reverse Split
Sentiment: Positive
View Wiseek Article
HBIO
Mar 17, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Harvard Bioscience Issues FY26 Guidance Projecting Revenue and EBITDA Growth
Sentiment: Positive
View Wiseek Article
HBIO
Mar 13, 2026, 8:20 AM EDT
Filing Type: 10-K
Importance Score:
9
Harvard Bioscience Reports Significant FY2025 Loss, Refinances Debt, and Enacts Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
HBIO
Mar 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Harvard Bioscience Reports Significant FY25 Net Loss Driven by Goodwill Impairment; Provides 2026 Guidance
Sentiment: Negative
View Wiseek Article
HBIO
Mar 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Harvard Bioscience Reports $56.7M FY25 Net Loss Driven by Goodwill Impairment; Revenue Declines
Sentiment: Negative
View Wiseek Article